Abstract: The evasion of apoptosis is a hallmark of cancer, heavily regulated by the BCL-2 family of proteins. In hematological malignancies such as myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), the overexpression of anti-apoptotic proteins like MCL-1 frequently drives disease progression and therapeutic resistance. S63845 is a highly specific, novel BH3-mimetic designed to selectively inhibit MCL-1. By mimicking natural pro-apoptotic signals, S63845 disrupts the interaction between MCL-1 and pro-apoptotic effectors, thereby restoring the intrinsic apoptotic pathway in malignant cells. Current literature highlights its potential to overcome resistance to other BCL-2 inhibitors, such as venetoclax, though the critical role of MCL-1 in healthy tissue survival necessitates careful clinical evaluation. This review synthesizes the pharmacological activity, molecular mechanisms, and future therapeutic perspectives of S63845 in the context of hematological malignancies.
1. Introduction
Hematological malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), are complex clonal disorders characterized by disrupted hematopoiesis and the evasion of programmed cell death. The intrinsic apoptosis pathway, governed by the BCL-2 family of proteins, plays a central role in this pathological survival [2]. The BCL-2 family consists of both anti-apoptotic proteins (such as BCL-2, BCL-XL, and MCL-1) and pro-apoptotic proteins (such as BAX, BAK, and BH3-only proteins). In many cancers, the overexpression of anti-apoptotic proteins raises the threshold for apoptosis, allowing malignant blasts to survive despite cellular damage [1].
To counter this, a class of targeted drugs known as BH3-mimetics has been developed. These molecules are designed to mimic the action of natural BH3-only proteins, binding to anti-apoptotic proteins and neutralizing their protective effects. While early BH3-mimetics and specific BCL-2 inhibitors like venetoclax have shown significant clinical success, acquired resistance remains a major hurdle. The upregulation of MCL-1 is a primary bypass mechanism for this resistance. Consequently, S63845, a highly specific MCL-1 inhibitor, has emerged as a critical investigational compound for treating refractory hematological malignancies [1][2].
2. Pharmacological Activity
S63845 has demonstrated potent pharmacological activity across diverse cancer models, proving to be both effective and tolerable in preclinical settings [1]. In the context of hematological malignancies, its primary value lies in its ability to target cells that have become refractory to standard treatments. For instance, in MDS and AML, treatment with BCL-2 inhibitors (like venetoclax) or hypomethylating agents often leads to a compensatory spike in MCL-1 expression, allowing cancer cells to bypass the drug's blockade [2]. S63845 actively breaks this resistance by directly neutralizing the upregulated MCL-1, thereby re-sensitizing the malignant blasts to apoptosis. Its efficacy in these resistant phenotypes positions it as a vital tool for advanced, relapsed, or refractory myeloid neoplasms [2].
3. Molecular Mechanism of Action
The molecular mechanism of S63845 is rooted in its function as a BH3-mimetic. Normally, the anti-apoptotic protein MCL-1 promotes tumor survival by hetero-oligomerizing with pro-apoptotic BCL-2 family members—such as BIM, BAK, NOXA, PUMA, and BID—effectively sequestering and neutralizing them [2]. S63845 is designed to mimic the BH3 domain of these pro-apoptotic proteins. It competitively binds to the hydrophobic groove of MCL-1. By occupying this binding site, S63845 displaces the pro-apoptotic effectors. Once freed, proteins like BAX and BAK can oligomerize and form pores in the mitochondrial outer membrane. This mitochondrial outer membrane permeabilization (MOMP) releases apoptogenic factors like cytochrome c into the cytosol, triggering the caspase cascade and culminating in the death of the cancer cell [1][2].
4. Structure-Activity Relationship (SAR)
The development of S63845 required overcoming significant structural challenges, as MCL-1 was historically considered a difficult target for specific mimetics [1]. The structural uniqueness of MCL-1 compared to other anti-apoptotic proteins like BCL-2 and BCL-XL is a key factor in S63845's design. Specifically, MCL-1 lacks the BH4 domain and possesses unusual amino acid residues within its BH3-binding pocket [2]. S63845 was structurally optimized to exploit these distinct topographical features, granting it the greatest specificity for MCL-1 over BCL-2 and BCL-XL [1]. This high selectivity ensures that the compound tightly binds the unique BH3 groove of MCL-1 without causing off-target inhibition of other BCL-2 family members, which is crucial for its targeted pharmacological profile.
5. Current Limitations
Despite its promising efficacy, the clinical application of S63845 and other MCL-1 inhibitors faces notable limitations. The most pressing concern is on-target toxicity. MCL-1 is not only a survival factor for malignant cells but is also essential for the survival and maintenance of vital healthy tissues, particularly cardiomyocytes and neurons [2]. Consequently, systemic inhibition of MCL-1 carries the inherent risk of severe cardiac and neurological side effects. Furthermore, as observed with other highly targeted BH3-mimetics like venetoclax, cancer cells exhibit a dynamic ability to acquire resistance through de novo missense mutations in the drug's binding pocket [1]. It is highly probable that prolonged exposure to S63845 could exert selective pressure, leading to similar acquired resistance mutations in the MCL-1 gene.
6. Future Perspectives
S63845 is currently advancing through clinical trials, representing a significant step forward in the targeted therapy of apoptosis [1]. Future research is heavily focused on combination therapies to maximize efficacy while potentially allowing for lower, less toxic dosing. Because MCL-1 overexpression is a known escape route for cells treated with BCL-2 inhibitors, combining S63845 with drugs like venetoclax, hypomethylating agents, or emerging PD-1/PD-L1 immune checkpoint inhibitors holds immense promise for treating refractory MDS and AML [2]. Additionally, ongoing structural studies of BH3-mimetics and their binding pockets will likely guide the next generation of MCL-1 inhibitors, aiming to preemptively overcome acquired resistance mutations and improve the therapeutic window [1].
